Please login to the form below

Not currently logged in
Email:
Password:

Jane Osbourn to chair BIA board

VP of R&D atMedimmune to chair BioIndustry Association board
Jane osbourn BIA

Jane Osbourn will be the new chair of the BioIndustry Associaton (BIA) board, effective January 2016.

Osbourn has 25 years of experience in the life sciences sector and currently serves as site leader and VP of research at MedImmune.

She said: “It has been my privilege to serve as a member of the BIA board since January 2014 and I am delighted to be taking over as chair during a period of such great opportunity for our industry.

“I am also very pleased to welcome our newly elected board members, who are recognised leaders and bring a diversity of ideas and backgrounds to the team.”

The new members of the board are Darrin Disley, chief executive of Horizon Discovery Group and David Hipkiss, chief business officer at Circassia Pharmaceuticals. Additionally Andrew Lightfood of Peptinnovate and Neil Murray of RedX Pharma will be joining.

Celia Caulcott, vice-provost of UCL Business has also been re-elected to the board.

Steve Bates, BIA chief executive added: “2015 has been a great year for the industry and I look forward to working with Jane and the board to build on this success in 2016. “I am confident that our multi-disciplined and diverse board will help to steer the industry through future challenges and represent the interests of all sizes of company in our sector.”

28th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....